Literature DB >> 30530042

The roles of ZEB1 in tumorigenic progression and epigenetic modifications.

Yu Zhang1, Lei Xu2, Anqi Li1, Xiuzhen Han3.   

Abstract

Highly expressed Zinc-finger E-box binding protein 1 (ZEB1) is significantly associated with the malignancy of various cancers. Signal transduction and activation of ZEB1 play important roles in cancer transformation and epithelial-mesenchymal transition (EMT). Emerging evidence suggests that ZEB1 drives the induction of EMT with activation of stem cell traits, immune evasion and epigenetic reprogramming. As an ideal target for EMT research, ZEB1 has been extensively studied for decades. However, the link between ZEB1 and epigenetic regulation of EMT has only recently been discovered. ZEB1 facilitates the epigenetic silencing of E-cadherin by recruiting multiple chromatin enzymes of E-cadherin promoter, such as histone deacetylases (HDACs), DNA methyltransferase (DNMT) and ubiquitin ligase. Destruction of the connection between ZEB1 and these chromatin-modifying enzymes may represent an efficient for treating cancer. In this review, we outlined the biological function of ZEB1 in tumorigenic progression and epigenetic modifications and elucidate its transcriptional network, which is a suitable potential target for the design of novel anticancer drugs.
Copyright © 2018 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  E-cadherin; EMT; Epigenetic; HDAC; MicroRNA; ZEB1

Mesh:

Substances:

Year:  2018        PMID: 30530042     DOI: 10.1016/j.biopha.2018.11.112

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  35 in total

1.  ZEB1 is a Subgroup-Specific Marker of Prognosis and Potential Drug Target in Medulloblastoma.

Authors:  Livia Fratini; Matheus Gibeke Siqueira Dalmolin; Marialva Sinigaglia; Alexandre da Silveira Perla; Caroline Brunetto de Farias; Algemir L Brunetto; André T Brunetto; Mariane da Cunha Jaeger; Rafael Roesler
Journal:  Neuromolecular Med       Date:  2022-06-18       Impact factor: 3.843

Review 2.  The Mechanism of Long Non-coding RNA in Cancer Radioresistance/Radiosensitivity: A Systematic Review.

Authors:  Wenhan Wu; Shijian Zhang; Jia He
Journal:  Front Pharmacol       Date:  2022-05-05       Impact factor: 5.988

3.  Epithelial-to-mesenchymal transition based diagnostic and prognostic signature markers in non-muscle invasive and muscle invasive bladder cancer patients.

Authors:  R Singh; U P Singh; V Agrawal; M Garg
Journal:  Mol Biol Rep       Date:  2022-05-20       Impact factor: 2.742

4.  From multi-omics integration towards novel genomic interaction networks to identify key cancer cell line characteristics.

Authors:  T J M Kuijpers; J C S Kleinjans; D G J Jennen
Journal:  Sci Rep       Date:  2021-05-18       Impact factor: 4.379

5.  Transcriptional repression of E-cadherin in nickel-exposed lung epithelial cells mediated by loss of Sp1 binding at the promoter.

Authors:  Xiaoru Zhang; Vinay Singh Tanwar; Cynthia C Jose; Hyun-Wook Lee; Suresh Cuddapah
Journal:  Mol Carcinog       Date:  2021-11-02       Impact factor: 4.784

6.  Down-Regulated CMTM2 Promotes Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma.

Authors:  Shidong Zhang; Run Tian; Chunhua Bei; Huixia Zhang; Juan Kong; Chuanjun Zheng; Xin Song; Di Li; Hongzhuan Tan; Xiaonian Zhu; Shengkui Tan
Journal:  Onco Targets Ther       Date:  2020-06-17       Impact factor: 4.147

Review 7.  Ubiquilin Networking in Cancers.

Authors:  Salinee Jantrapirom; Luca Lo Piccolo; Dumnoensun Pruksakorn; Saranyapin Potikanond; Wutigri Nimlamool
Journal:  Cancers (Basel)       Date:  2020-06-15       Impact factor: 6.639

8.  A New TGF-β1 Inhibitor, CTI-82, Antagonizes Epithelial-Mesenchymal Transition through Inhibition of Phospho-SMAD2/3 and Phospho-ERK.

Authors:  Ji-Hoon Jeong; Hyunhee Kim; Seung-Ho Park; Hayeon Park; Minseok Jeong; Sungmin Kwak; Gi-Jun Sung; Ji-Hye Song; Younghwa Na; Kyung-Chul Choi
Journal:  Biology (Basel)       Date:  2020-06-28

9.  PCNP promotes ovarian cancer progression by accelerating β-catenin nuclear accumulation and triggering EMT transition.

Authors:  Pengzhen Dong; Hao Fu; Lin Chen; Shihui Zhang; Xin Zhang; Huimin Li; Dongdong Wu; Xinying Ji
Journal:  J Cell Mol Med       Date:  2020-06-16       Impact factor: 5.310

10.  Inhibiting the redox function of APE1 suppresses cervical cancer metastasis via disengagement of ZEB1 from E-cadherin in EMT.

Authors:  Qing Li; Zhi-Wei Zhou; Wei Duan; Cheng-Yuan Qian; Shu-Nan Wang; Meng-Sheng Deng; Dan Zi; Jian-Min Wang; Cheng-Yi Mao; Guanbin Song; Dong Wang; Kenneth D Westover; Cheng-Xiong Xu
Journal:  J Exp Clin Cancer Res       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.